available online on <u>www.ijpba.in</u> International Journal of Pharmaceutical and Biological Science Archive NLM (National Library of Medicine ID: 101732687) Index Copernicus Value 2023: 75.83 Volume 13 Issue 3; 2025; Page No. 28-39

Development and Validation of RP-HPLC Method for the Determination of Sorafenib Tablet

Prajapati Laxman¹, Goyal Pramod Kumar², Sharma Piush³

Department of Pharmaceutical Chemistry, Maharshi Arvind College of Pharmacy, Ambabari, Jaipur-302039, Rajasthan, India

Article Info: Received: 24-03-2024 / Revised: 17-04-2024 / Accepted: 26-04-2025 *Correspondence: Prajapati Laxman Conflict of interest statement: No conflict of interest

Abstract

Sorafenib, an oral multi-kinase inhibitor, is an extensively utilized in oncology for its antineoplastic Department of Pharmaceutical Chemistry, Maharshi Arvind College of Pharmacy, Ambabari, Jaipur-302039, Rajasthan, India properties. Accurate quantification of Sorafenib in pharmaceutical formulations is critical for quality control and therapeutic efficacy. Reverse phase high-performance liquid chromatography offers a sensitive, rapid, precise, accurate high-performance liquid chromatographic method for the estimation of Sorafenib (SOR) in the tablet dosage form. Chromatographic separation of SOR was carried out utilizing thermo-scientific model C18 column (4.6 mm i.d. X 250 mm; 5µm particle size) (based on 99.99 % ultra-high purity silica) using mobile phase that consisting of acetonitrile: methanol (40:60 v/v) at a flow rate of 1.0 mL/min. The absorption maximum (λ max) of SOR in the mobile phase was found to be 266 nm. It had a retention time of 3.222 min. The calibration curve was in linear function of the drug in the concentration range of 2-10 μ g/mL (r2 = 0.999) for the optimized method. The regression equation for SOR was found to be Y = 68228 x + 8071. The Detection Limit (DL) & Quantitation Limit (QL) results of SOR were found to be 0.525 µg/mL and 1.595 µg/mL respectively. The developed method was validated in pursuance of ICH Q2 (R1) guidelines. The method was linear, precise, accurate with recoveries in the range of 98 - 102 %, and minimum values of % RSD indicate the accuracy of the method. The detailed quantitative results of the study show that this method is robust, precise, accurate, and costeffective. Thus, the developed RP-HPLC method is reproducible and demonstrating its suitability for routine analysis of Sorafenib in pharmaceutical formulations.

Keywords: Sorafenib, RP-HPLC, Pharmaceutical formulation, Validation.

Introduction

Sorafenib (SOR) is 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino) phenoxy]-N-methyl pyridine-2-carboxamide. Its molecular formula is C21H16ClF3N4O3. SOR is an anti-cancer drug that is a protein kinase inhibitor.

A thorough literature survey reveals that few analytical methods are reported for the determination of SOR in bulk & pharmaceutical preparations and in biological fluids, which include, UV spectrophotometric method(1-2), RP-HPLC (3-8), HPTLC (9), HighPerformance liquid chromatography with tandem mass spectroscopy (10-12).

However, most of the available methods have limitations such as arduous sample preparations, increased solvent consumption, long run times for biological samples, low sensitivity, uneconomical, and also have reduced symmetry. The present study focused these minimizing limitations and on developing a simple, accurate, precise, and reliable RP-HPLC method for the estimation of SOR in the pharmaceutical dosage form.



Figure 1.a: Chemical structure of Sorafenib

Materials and Methods

Chemicals and Reagents

Soranib 200 mg, marketed tablet formulation manufactured by Cipla Ltd., Purchased from a local pharmacy store. HPLC graded Methanol, Acetonitrile, Water and AR grade HCl, Sodium Hydroxide, Hydrogen Peroxide were purchased from Merck specialties Pvt. Ltd., Mumbai, India. Other excipients were prepared in our laboratory.

Instrumentation and optimization of chromatographic conditions

For UV detection of the samples, ELICO SL-210 UV spectrophotometer with 1 cm matched quartz cells were used for all spectral and absorbance measurements, and solutions were prepared in methanol. For HPLC. the chromatographic system consists of Agilent technologies - 1260 series with G1311C Quat pump VL, Thermo scientific C18 column, 1260 series with G11511D DAD VL detector was used. The data was acquired and processed by chrome elite utilizing ΕZ software. Chromatographic separation was performed on Thermo-scientific model C18 column (4.6 mm i.d. X 250 mm; 5 µm particle size) (based on 99.99 % ultra-high purity silica). using mobile phase that consisting of acetonitrile: methanol (40:60 v/v) at a flow rate of 1.0 mL/min, the runtime was set for 12 min and the eluted drug was detected at 265.5 nm with PDA detector. The sample injection volume was 20 μ l. The column was maintained at a constant temperature of about 25^oC.

Method development and optimization of chromatographic conditions

For HPLC development, various mobile phases containing HPLC grade water, acetonitrile, methanol in different ratios with or without buffers, and various flow rates were performed. A good symmetrical peak was found when the mobile phase comprising a mixture of acetonitrile: methanol (40:60 v/v).

Selection of detection wavelength

In the present study, the drug solutions of 10 μ g/ml of SOR were prepared and scanned over a range of 200 - 400 nm. It was observed that the drug showed maximum absorbance at 265.5 nm which was chosen as the detection wavelength for the determination of SOR. The overlay spectrum (2-10 μ g/mL) is shown in Figure 1.b.



Figure 1.b: Overlay Spectrum of Sorafenib

Preparation of the mobile phase

The mobile phase was prepared by mixing acetonitrile and methanol in the proportion of 40: 60 v/v. The prepared mobile phase was filtered through a 0.45 μ m nylon membrane filter and degassed by sonication.

Preparation of Stock and working standard solution

Precisely weighted 100 mg of SOR was transferred into 100 mL volumetric flask, dissolved, and diluted up to the mark with mobile phase to get a stock solution containing 1.0 mg/mL of SOR. Aliquots of stock solution were diluted with mobile phase to attain the calibration standard solutions over the range of 2, 4, 6, 8, and 10 μ g/mL.

Method development and optimization

The optimized HPLC conditions of several mobile phases with different compositions were tested to develop an optimization of chromatographic conditions like tailing factor, peak shape, and the number of theoretical plates. Optimized chromatographic conditions, system suitability parameters for estimation of SOR by proposed gradient RP- HPLC method are depicted in Table 1.a.

Table 1.a: O	ntimized	chromatogran	phic condition	is for the pr	oposed HPLC	method
	pumizeu	chi omatogi ap		is for the pr	oposcu III LC	meenou

Parameter	Chromatographic conditions		
	Thermo scientific model C18 Column (4.6 mm i.d., X 250 mm;		
Column	5 μm particle size) (based on 99.999 % ultra-high purity silica)		
Mobile phase	Acetonitrile: methanol (40: 60 v/v)		
Flow rate	1 mL/min		
Run time	12 minutes		
Detector	1260 Diode Array Detector.		
Detection wavelength	UV at 265.5 nm		
The volume of the injection loop	20 μL		
Temperature	Room temperature (25 °C)		

Method validation

Validation is a process of establishing documented evidence, which provides a high degree of assurance that a specific activity will consistently produce a desired result or product meeting its pre-determined specifications and quality characteristics. The method was validated as per ICH guidelines (13-18).

System suitability: The system suitability parameters like theoretical plates, retention time, tailing factor, were studied and found satisfactory. The results are shown in Table 1.b.

System suitability parameters	Limits	SOR	
Tailing factor (T)	≤ 2.0	1.122	
Number of theoretical plates	NLT 2000	8768	
Theoretical plates per meter (N)*	-	1,66,592	
Retention time*	-	3.223 minutes	
SD for peak area and RT		0.0228	
% RSD	NMT 2.0	0.5628	

* Average of five determinations, SD = Standard deviation, RSD = relative standard deviation.

Specificity

Blank, standard, system suitability, placebo, placebo spiked with the analyte, test preparations, individual impurities, and spiked test preparations were analyzed as per the method to examine the interference of blank and placebo with SOR peaks. The peak purity angles are mentioned in Table 1.c, and the specificity study of SOR is mentioned in Table 2. The results of the sample and placebo chromatograms are represented in Figure 1.b & Figure 2 respectively.

Sample	Analyte	Purity angle	Purity threshold
Standard preparation	SOR	0.138	0.222
Placebo + analyte preparation	SOR	0.138	0.227
Test preparation	SOR	0.132	0.229
Spiked test preparation	SOR	0.136	0.222

There should be no significant NMT 0.2 % of target concentration from blank, placebo, and known impurities with the analyte. The Peak purity of the analyte peak should meet the requirement. The purity angle shall be less than

the purity threshold. There is no interference observed to analyte peaks, and the peak purity value complies, thus proving the specificity of the method. The results of the specificity study are mentioned in Table 2.

Table 2: Results of specificity study for SOR			
Name of the solution	Retention time (Rt) minutes		
Mobile phase (blank)	No interference at RT of analyte peak		
Placebo	No interference at RT of analyte peak		
SOR 10 µg/mL (sample)	3.223 minutes		



Figure 2: Sorafenib placebo chromatogram

Precision

System precision: For RP-HPLC, six replicate injections of standard and blank were injected into the HPLC system. The values of the standard SOR (10 μ g/mL) are given below in Table 2.a.

Table 2.a:		
Injection No.	Area Response	
1	686384	
2	686432	
3	686120	
4	686542	
5	686024	
6	686438	
Mean	686323.3	
% RSD	0.02967	

Method precision & Intermediate precision: For method precision, six test preparations were analyzed as per the methodology representing a single batch, and the assay was determined for

Table 2: Results of	specificity study for SOR

the same. The % RSD for assay of six test preparations should not be more Table 2.a: System Precision than 2.0. The results are well within acceptance criteria, and the % RSD observed for assay values indicates the precision of the method. The resultant values for the drug are given below in Table 2.b.

Injection No.	Method Precision	Intermediate Precision
1	98.3	99.3
2	99.6	99.6
3	98.4	98.2
4	99.4	98.5
5	99.1	99.4
6	98.7	99.6
Mean	98.1667	99.1000
% RSD	0.540332	0.605449
Cumulative	RSD	1.14578

Precision at different levels: Precision at different levels of the analytical method was determined in the concentration range of 50 %, 100 %, 150 %, their values are mentioned in Table 2.c.

Injection No.	Method Precision	Intermediate Precision
1	98.3	99.3
2	99.6	99.6
3	98.4	98.2
4	99.4	98.5
5	99.1	99.4
6	98.7	99.6
Mean	98.1667	99.1000
% RSD	0.540332	0.605449
Cumulative	RSD	1.14578

Table 2.b: Complied data of Method Precision & Intermediate Precision

Precision at different levels: Precision at different levels of the analytical method was determined in the concentration range of 50 %, 100 %, 150 %, their values are mentioned in Table 2.c.

Table 2.c: Precision at 50 %, 100 %, 150 % (Precision at different levels)

S. No.	50%	100%	150%
1	145328	288941	427689
2	145742	287465	428864
3	146230	288129	428513
4	145896	288752	428567
5	145246	289148	427614
6	145847	288465	428954
Mean	14571.8	288483.333	428366.833
% RSD	0.25417	0.21291251	0.13530080



Figure 2.a: Calibration graph of Sorafenib by RP- HPLC

SUMMARY OUTPUT								
	itatistics							
Multiple R	0.999505293							
R Square	0.999010831							
Adjusted R Square	0.998763539							
Standard Error	8981.168063							
Observations	6							
ANOVA								
	df	SS	MS	F	Significance F			
Regression	1	3.25856E+11	3.25856E+11	4039.798238	3.6704E-07			
Residual	4	322645519.1	80661379.78					
Total	5	3.26178E+11				_		
	Coefficients	Standard Error	t Stat	P-value	Lower 95%	Upper 95%	Lower 95.0%	Upper 95.0%
Intercept	8071.047619	6500.092225	1.241682016	0.282188065	-9976.1016	26118.197	-9976.1016	26118.197
X Variable 1	68228.15714	1073.454901	63.55940716	3.67042E-07	65247.7685	71208.546	65247.7685	71208.546

Figure 2. b: The summary output of ANOVA study of Sorafenib

Accuracy (Recovery studies): A known amount of drug was spiked with placebo at three different levels in triplicate preparations. The samples were then analyzed as per the proposed standard method. The accuracy studies are mentioned in Table 3 a. The precision at accuracy results is mentioned in Table 3.b.

Table 5.a. Results of Accuracy study						
% Recovery Level		Amount Added (mg)	Amount recovered (mg)	% Recovery		
	1	12.14	12.09	99.5		
50 %	2	12.21	12.11	99.1		
	3	12.09	11.96	99.6		
	1	24.53	24.11	98.2		
100 %	2	24.65	24.49	99.3		
	3	24.72	24.61	99.5		
	1	36.91	36.78	99.6		
150 %	2	37.02	36.88	99.6		
	3	36.89	36.72	99.5		

Table 3.a: Results of Accuracy study

Table 3.b: Results of Precision at Accuracy study

S. No.	Concentration % of spiked level	% recovery	% RSD
1	50 %	99.4	0.2661
2	100 %	99.0	0.7070
3	150 %	99.6	0.5798

Robustness: The robustness of the method was determined for the system suitability and assay value under variable conditions. The robustness of the analytical method was established by demonstrating its reliability against deliberate changes in the chromatographic conditions. The robustness of the method of SOR is mentioned in Table 3.c.

Parameters	Optimized	Used	Retention	Plate	Peak	Remarks
			time (min)	count \$	asymmetry #	
Flow rate		0.8	3.298	8820	1.11	*Robust
(± 0.2 mL/min)	1.0	mL/min				
	mL/min	1.0	3.223	8768	1.12	*Robust
		mL/min				
		1.2	3.19	8720	1.11	*Robust
		mL/min				
Detection		260 nm	3.223	8760	1.13	Robust
wavelength (\pm 5	265 nm	265 nm	3.223	8768	1.20	Robust
nm)		270 nm	3.223	8764	1.13	Robust
Mobile phase		55:45 v/v	3.327	8779	1.10	*Robust
composition	60:40 v/v	60:40 v/v	3.223	8768	1.12	*Robust
Methanol:		65:35 v/v	3.209	8789	1.17	*Robust
Acetonitrile						
(± 5 %)						

I ADIE J.C. RESULLS OF RODUSTILESS STUD	Table 3.c:	Results	of Robustness	study
---	------------	---------	---------------	-------

Acceptance criteria (Limits): #Peak Asymmetry < 1.5, ^{\$} Plate count > 2000, * Significant change in Retention time

Limit of Detection is the lowest concentration in a sample that can be detected but not necessarily quantified under the stated experimental conditions. The limit of quantitation is the lowest concentration of analyte in a sample that can be determined with acceptable precision and accuracy. The LOD and LOQ are 0.525 µg/mL and 1.595 µg/mL respectively.

Results and Discussion: The above-mentioned SOR is relatively polar, an RP-HPLC method was used. The column for the separation was a C18 column that has an internal diameter of 4.6mm, length of 250 mm, and 5μ m particle

size. Multiple numbers of trials were performed using various buffer solutions with various compositions of methanol, ethanol, acetonitrile, and HPLC grade water and variable flow rates. Eventually, optimum separation was obtained with a mixture of acetonitrile and methanol (40:60 v/v).

The mobile phase flow rate was adjusted at 1mL/min, and the detection wavelength was set at 266 nm. Thus, a proper chromatographic peak was obtained with excellent symmetry and the least peak tailing. The chromatograms of various concentrations were shown in Figure 3 – Figure 3.d.



Figure 3: Standard chromatogram of Sorafenib (2 µg/mL)



Figure 3.a: Standard chromatogram of Sorafenib (4 µg/mL)







Figure 3.c: Standard chromatogram of Sorafenib (8 µg/mL)



Figure 3.d: Standard chromatogram of Sorafenib (10 µg/mL)

System suitability was conducted as per the methodology system suitability solution, and six replicates of standard preparation were injected into HPLC. The tailing factor was found to be 1.122. The number of theoretical plates was 8768, the number of theoretical plates per meter was 1,66,592. The retention time was found out to be 3.223 minutes, and the % RSD was

calculated to 0.5628. The results were well within the acceptance criteria, and the study concludes the suitability of the analytical system for analysis. For specificity studies, blank, standard, system suitability, placebo, test preparations, individual impurities, placebo spiked with the analyte, and spiked test preparations were analyzed to examine the interference of blank and placebo with SOR peaks. The purity angle for standard preparation is 0.139, for placebo plus analyte preparation is 0.138, for test preparation is 0.132 and spiked test preparation is 0.137. No interference was observed in analyte peaks, and peak purity values comply, thus proving the specificity of the method.

The precision of the method was examined by System precision. Method. using and Intermediate precisions. Various levels of concentration were taken in six replicate Method and Intermediate samples. For precisions, the % RSD was found to be 98.166 and 0.60544. The % RSD of the System precision was found to be 0.02967. The precision at different levels was mentioned in Table 2.C. The results are well within the acceptance criteria, and the % RSD observed for the replicate injections indicates the precision of the HPLC used, assay values indicate the precision of the method.

The linearity of SOR was determined in the concentration range of 2 μ g/mL to 10 μ g/mL of the test concentration. The squared correlation coefficient value was found to be 0.99901, which is well within the limit.

To determine the accuracy of the SOR, the drug was spiked with a placebo at three different levels in triplicate preparations. The results of accuracy are mentioned in Table 3.a, and the results of precision at accuracy are given in Table 3.b. The mean % recovery at each level was found out to be within limits i.e., 98.0 % to 102.0 %

The robustness of the HPLC was determined for the suitability and assay value under multiple variable conditions like Flow rate change, Wavelength change, and change in mobile phase composition. The results are mentioned in Table 3.c. The LOD and LOQ of SOR were found out to be $0.526 \mu g/mL$ and $1.594 \mu g/mL$, respectively.

Application of the developed method for marketed formulation (Assay)

For the assay of pharmaceutical formulation, 20 tablets of Soranib marketed formulation (SOR 200 mg) were weighed, the average weight was calculated, and a quantity of tablet powder equivalent to 100 mg of SOR was accurately weighed and transferred into a 100 mL volumetric flask containing 30 mL of the mobile phase. The solution was ultra-sonicated for about 15 minutes, filtered through a Whatman filter paper (0.45 μ m) nylon filter, and the filtrate was made up to volume with the mobile phase. The concentration was 1 mg/mL. Transfer 1 ml of the filtered sample solution to 10 mL volumetric flask and made up to volume with mobile phase to get 100 µg/mL. This is used as a working solution for the preparation of the assay. Then 0.2 ml of this solution is transferred into a 10 ml volumetric flask and made up to volume to obtain 2 μ g/mL which is used for the assay. The assay results are presented in Table 4. a. The representative sample chromatogram of SOR is shown in Figure 4.a.

Table 4.a. Assay results of marketed for mulation							
S. No. Formulation Labeled claim Amount found Mean % recovery± SD* % RSD							
1	Soranib tablets	200 mg/tablet	199.9 mg/tablet	99.95 ± 12	1.23		
*Average of six determinations, SD denotes standard deviation, RSD denotes % relative							

 Table 4.a: Assay results of marketed formulation

standard deviation.



Figure 4.a: SOR sample chromatogram

Summary: To summarize the methods employed and the results obtained in the study of SOR, it is mentioned below in Table 4.b.

S. No.	Validation Parameter	Acceptance Criteria	Results
1	System Suitability	 The ICH regulation between degradants peak and SOR peak in the system suitability should not be less than 2.0. The ICH tailing factor for SOR peak in standard preparation should not be less than 2.0. The ICH theoretical plate count for the SOR peak in standard preparation should not be less than 3000. The % Relative standard deviation in six replicate injections of standard preparation should not be more than 2.0 %. 	Complies
2.	Specificity Interference from blank, placebo, and impurities	 There should not be any significant interference (NMT 0.2 % of the target concentration) from blank, placebo, and impurities with the analyte. Peak purity of the analyte peak should pass (Purity angle should be less than Purity threshold). 	No interference observed, and peak purity complies
3.	Precision		
	1. System precision	% RSD for six replicate injections should not be more than 2.0.	SOR: % RSD - 0.02967
	2. Method precision	% RSD for assay of six test preparations should not be more than 2.0.	SOR: % RSD - 0.54033
	3. Intermediate precision	 % RSD for the assay of six test preparations should not be more than 2.0. Cumulative % RSD of 12 determinations (method and intermediate precision) should not be more than 2.0. 	SOR: %RSD - 0.605449 SOR: Cumulative %RSD - 1.14578
	4. Precision at different levels	% RSD for six replicate injections at 50 %, 100 %, 150 % levels should not be more than 2.0	50% - 0.25417 100% - 0.21291 150 % - 0.13530
4.	Linearity	The squared correlation coefficient should not be less than 0.997	0.99901
5.	Accuracy Study	The mean % recovery should be between 98.0 to 102.0	50 % - 99.4 100 % - 99.0 150 % - 99.6
6.	Robustness	 System suitability should pass. Assay value should not be more than ± 2 % from the mean value of method precision, or the result should be within the range of method precision results. 	Complies

Table 4.b: Summary of the RP-HPLC of Sorafenib

Conclusion

The current study demonstrated a validated RP-HPLC method for the estimation of SOR available as the tablet dosage form. The method was completely validated and showed satisfactory results. The method was free from the interference of the other active ingredients and additives used in the formulation.

The RP-HPLC method for the determination of SOR has various advantages like less solvent consumption, low retention time, good peak symmetry accurate, precise and robust. The results of the study indicate that the developed method was found to be accurate, precise, linear, sensitive, simple, economical, and reproducible, which has a short run time, which makes the method rapid. Hence it can be concluded that this method may be employed for the routine quality control analysis of SOR in active pharmaceutical preparations.

References

- Ramalingam K, Jayachandran E. UV spectrophotometric estimation of SOR in pure and tablet dosage form. J Pharm Res. 2011; 4(10): 3705-3706.
- Ravisankar P, Srinivasa Babu P, Munaza Taslim Sk, Kamakshi K, Lakshmi Manasa R. Development and Validation of UV -Spectrophotometric method for determination of SOR in Pharmaceutical Dosage Form and its Degradation behavior under Various Stress conditions. Int. J Pharm Sci Rev Res. 2019; 56(1): 12-17.
- 3. Ramesh J, Senthil Kumar N. Optimization of stability indicating RP-HPLC method for the estimation of an anti- cancer drug SOR Tosylate in the pure and pharmaceutical dosage form. Int. J. of Pharmacy and Analytical Research. 2017; 6(1): 141-152.
- VenkataRao S, Ramu G, Biksham Babu A, Neeharika T, Rambabu C, Determination of SOR In Bulk and Tablet Formulation by a New Validated Reverse Phase High Performance Liquid Chromatography. Rasayan J. Chem. 2011; 4(2): 477-480.
- 5. Miki Shimada, Hoshimi Okawa, Takahiro Maejima, Toshiki Yanagi, Kanehiko Hisamichi, Masaki Matsuura, et al. A Quantitative HPLC-UV Method for Determination of Serum SOR and SOR N-

Oxide and Its Application in Hepatocarcinoma Patients. Tohoku J. Exp. Med. 2014; 01(233): 103-112.

- Hassan A Alhazmi, Dhaif Allah Moraya, Emad Alahdal, Mohammed Kariri, Mohammed Al Bratty, Ziaur Rehman, et al. Ultrafast monolithic HPLC method for simultaneous quantification of the anticancer agents, Imatinib and SOR: Application to tablet dosage forms. Trop J Pharm Res, 2018; 17(6): 1127-1134.
- Ravisankar P, G. Sai Kushal Gunturu, Ramya V. Development and validation of RP-HPLC method for the determination of Sorafenib (A novel kinase inhibitor drug) In Pharmaceutical dosage form. Int J Life Sci Pharma Res. 2019; 693-698. Doi: http://dx.doi.org/10.22376/ijpbs/ijlpr/SP10/J an/2020.1-881.
- 8. Ravisankar P, Niharika A, Srinivasa Babu P, An inproved RP- HPLC method for the determination and validation of levetiracetam in bulk and pharmaceutical formulation, Int. Res. J. Pharm. 2013; 6(8): 537-543.
- Powar Amol Shivaji, Gowda Pramila T. HPTLC Determination of SOR Tosylate In Bulk Drug and Pharmaceutical Dosage Form. International Research Journal of Pharmacy. 2012; 31; 3(2): 108-110.
- Lokesh Jain, Erin R. Gardner, Jurgen Venitz, William Dahut, William D. Figg. Development of a Rapid and Sensitive LC-MS/MS assay for the Determination of SOR in Human Plasma. J Pharm Biomed Anal. 2008; 46(2): 362-367.
- 11. Ming Zhao, Michelle A. Rudek, Ping He, Prank-Thorsten Hafner, Martin Radtke et al. A rapid a sensitive method for determination of SOR in human plasma using a liquid chromatography/tendem mass spectrometry assay. Journal of chromatography B. 2007; 846(1-2): 1-7.
- 12. Allard M et al. Simultaneous analysis of regorafenib and Sorafenib and three of their metabolites in human plasma
- 13. using LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2017; 142(5): 42-48.
- 14. Ravisankar P, Gowthami S, Devala Rao G. A review on analytical method development, Indian journal of research in

pharmacy and Biotechnology. 2014; 2(3): 1183-1195.

- 15. Ravisankar P, Naga Navya Ch, Pravallika D, Navya Sri D. A review on step-by-step analytical method validation. IOSR J Pharm. 2015; 5(10): 7-19.
- Panchumarthy Ravisankar, Anusha S, Supriya K, Ajith Kumar U, Fundamental chromatographic parameters. Int. J. Pharm. Sci. Rev.Res., 2019; 55(2): 46-50.
- Lavanya Chowdary G, Ravisankar P, Akhil Kumar G, Mounika K, Srinivasa Babu. Analytical method validation parameters: An updated review. Int. J. Pharm. Sci. Rev.Res., 2020; 61(2): 1-7.
- 18. Gennaro A.R., Remington., The sciences and practice of pharmacy, 28th edn,

Luppincott, Williams and Wilkins, Baltimore, Maryland, USA, 2000,pp 534 – 549.

- 19. Hobart H Willard, Lynne L Merritt, John A Deen, Frank A Settle, Instrumental method of analysis , published by CBS publishers, Pp 600-603.
- 20. Ravisankar P, Sai Geethika A, Rachana G, Srinivasa Babu P, Bhargavi J, Bioanalytical method validation: A Comprehensive review., Int. J. Pharm. Sci. Rev. Res., 2019; 56(1): 50-58.
- ICH Q2 (R1). Validation of analytical procedures, Text and methodology, International Conference on Harmonization. Geneva. 2005 Nov; 1-17.